BioSpace News Archive

Today, Bayer announced a five-year partnership with the World Federation of Hemophilia (WFH) Humanitarian Aid Program, which will bring education, training, and Bayer’s full portfolio of recombinant Factor VIII (rFVIII) treatments to healthcare professionals in more than 60 countries where access to care is limited.

Danish manufacturer of service robots for the healthcare, hospitality, construction and agricultural sectors, Blue Ocean Robotics, wins one of the most prestigious awards in the robotics industry, the IERA Award 2019.

The partner of CStone Pharmaceuticals, Agios Pharmaceuticals, Inc. announced that the global Phase 3 ClarIDHy trial of TIBSOVO in previously treated cholangiocarcinoma patients with an isocitrate dehydrogenase 1 (IDH1) mutation met its primary endpoint.

Lunaphore Technologies S.A., a Swiss medtech firm developing innovative next-generation equipment for cancer research and tissue diagnostics, announces a new rapid multiplexing application for its LabSat™ Research instrument

Lannett Company, Inc. announced the appointment of Melissa V. Rewolinski, PhD, to its board of directors, effective July 1, 2019.

Strategic agreement leverages physics-based models to deliver mission simulations with unparalleled accuracy and reliability

ADVANZ PHARMA Corp. commented on the issuance by the UK Competition and Markets Authority of a Statement of Objections to various parties, including ADVANZ PHARMA, related to competition matters pertaining to the Company’s medicine, prochlorperazine buccal tablets.

MGI, a subsidiary of global genomics leader BGI Group, announced it will begin marketing a total solution for single cell RNA Sequencing as part of the 10x Genomics’ Compatible Product Partner Program on MGI’s MGISEQ and BGISEQ sequencing platform.

Can-Fite BioPharma Ltd. announced that it has been selected for a podium presentation in a session of ‘Selected Abstracts of Excellence’ titled, “Namodenoson anti-NAFLD/NASH Activity is Mediated via De-regulation of the Wnt/β-catenin Pathway” at the 2nd Annual International Conference on Fatty Liver in Berlin, Germany which takes place on June 27-29, 2019.

ZyVersa Therapeutics, Inc. is pleased to announce appointment of international investor, Andrew Kim, to its Board of Directors.